A phase II trial with safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma.

Sminu Bose, Matthew Ingham, Brian A. Van Tine et al.|Journal of Clinical Oncology|2023

Cited by 2